An overview of Compassionate Use Programs in the European Union member states

The journal Intractable & Rare Diseases Research has published an article about the compassionate use programs. The past decade witnessed rapid development of novel drugs and therapeutic biological agents. The marketing authorization for novel therapies is often time consuming and distressing for patients. Earlier clinical trials were the only way to access new drugs under development. However, not every patient meets the enrolment criteria, and participation is difficult for patients with life-threatening, long-lasting or seriously debilitating diseases like rare diseases. The full-text article you can find here.